1332855-98-7

Basic information

• Product Name: tert-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate
• Synonyms: tert-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate
• CAS NO: 1332855-98-7
• Molecular Weight: 268.288
• Mol File: 1332855-98-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate(1332855-98-7)
• EPA Substance Registry System: tert-butyl 2-(2-(4-fluorophenyl)acetyl)hydrazinecarboxylate(1332855-98-7)

Safety Data

• Hazardous Substances Data: 1332855-98-7(Hazardous Substances Data)

Upstream product

• 405-50-5 p-Fluorophenylacetic acid 
• 870-46-2 t-butoxycarbonylhydrazine 
• 459-04-1 4-Fluorophenylacetyl chloride 

Downstream Products

• 34547-28-9 4-fluorophenylacetic acid hydrazide 
• 1338091-26-1 5-benzyloxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid N'-[2-(4-fluorophenyl)acetyl]hydrazide 
• 1338091-27-2 5-benzyloxy-6-[5-(4-fluorobenzyl)-[1,3,4]oxadiazol-2-yl]-N₃-methyl-3H-pyrimidin-4-one 
• 1338091-28-3 5-benzyloxy-6-[5-(4-fluorobenzyl)[1,3,4]oxadiazol-2-yl]-3-methyl-3H-pyrimidine-4-thione 
• 1338091-29-4 5-benzyloxy-6-[5-(4-fluorobenzyl)[1,3,4]oxadiazol-2-yl]-3-methyl-3H-pyrimidin-4-one oxime 
• 1338091-05-6 6-[5-(4-fluorobenzyl)[1,3,4]oxadiazol-2-yl]-5-hydroxy-3-methyl-3H-pyrimidin-4-one 
• 1338091-04-5 C₁₄H₁₂FN₅O₃ 
• 1338091-07-8 C₁₇H₁₃FN₆O₂ 
• 1338091-35-2 C₁₇H₁₄FN₅O₃ 
• 1338091-10-3 C₁₇H₁₂FN₅O₂ 
• 1616277-90-7 C₂₄H₂₁FN₂O₆S 
• 1616277-91-8 C₁₃H₁₇FN₂O₂S 
• 1616277-98-5 ethyl 3-(benzyloxy)-1-((tert-butoxycarbonyl)(methyl)amino)-5-(5-(4-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-4-oxo-1,4-dihydropyridine-2-carboxylate 
• 1616277-99-6 3-(benzyloxy)-1-((tert-butoxycarbonyl)(methyl)amino)-5-(5-(4-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, Y, R1, R2 and R11 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS

The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.